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Abstract: Cancer metastasis, the final stage of tumor progression, is a complex process governed 
by the interplay of multiple types of cells and the tumor microenvironment. One of the aspects 
of this interplay involves the release of various factors by the tumor cells alone or by forcing 
other cells to do so. As a consequence of these actions, tumor cells are prepared in favorable 
conditions for their dissemination and spread to other sites/organs, which guarantees their escape 
from immunosurveillance and further progression. Tumor-derived extracellular vesicles (TEVs) 
represent a heterogeneous population of membrane-bound vesicles that are being actively released 
by different tumors. The array of proteins (i.e., receptors, cytokines, chemokines, etc.) and nucleic 
acids (i.e., mRNA, miR, etc.) that TEVs can transfer to other cells is often considered beneficial for the 
tumor's survival and proliferation. One of the proteins that is associated with many different tumors 
as well as their TEVs is a cluster of differentiation 44 in its standard (CD44s) and variant (CD44v) 
form. This review covers the present information regarding the TEVs-mediated CD44s/CD44v 
transfer/interaction in the context of cancer metastasis. The content and the impact of the transferred 
cargo by this type of TEVs also are discussed with regards to tumor cell dissemination.
Keywords: tumor-derived extracellular vesicles; extracellular vesicles; CD44; hyaluronan; can­
cer metastasis
1. Introduction
The search for an effective target(s) in anti-tumor therapy has been ongoing, since 
the dawn of modern medicine. Despite many attempts at finding such targets, a surgical 
procedure followed by chemotherapy and/or radiotherapy still seems to be the best option 
to have a chance at eradicating tumors, however, the outcomes, very often, turn out to be 
unsatisfactory. The ability of tumors to 'trick' the immune system by becoming 'invisible', 
one way or another, is still a very serious challenge to the scientific community. The 
decades' worth of research has provided one conclusion for certain; that the tumor-immune 
system interactions are not controlled by a single 'sw itch', but are rather governed by a 
very complex network of mutual, ongoing interactions resembling a constant battlefield. In 
appreciation of this complexity, the search and utilization of multiple targets simultaneously 
in an attempt to shut down tumor cell machinery is probably the best option for a successful 
anti-tumor strategy.
In over a decade now, the field of extracellular vesicles (EVs) has captured the attention 
of many groups engaged in tumor research. The ability of the tumor cells to release 
tumor-derived extracellular vesicles (TEVs) sheds new light on the tumor-immune system 
interactions [1,2]. This recently discovered form of intercellular communication has proven 
that tumor cells can modify the immune cells either directly, by transferring different 
factors (receptors, proteins, nucleic acids, etc.) using TEVs [3] or indirectly, by forcing the 
surrounding cells to release their respective EVs with appropriate 'cargo' supplementing 
tumor's further progression [4]. These types of EVs/TEVs exchange seem to play a pivotal
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role in cancer metastasis; the final stage of tumor development, which proves too often 
terminal [3,5].
Another important player that is associated with cancer developm ent/m etastasis is 
a cluster of differentiation 44 (CD44) in its standard (CD44s) and variant (CD44v) form. 
The expression of CD44 has been elevated in many types of cancer [2], often localizing in 
tumor cells' filopodia [6], suggesting its role in cellular motility; a prerequisite for cancer 
spreading. Moreover, due to the ability to sequester growth factors (i.e., HGF, FGF, EGF) 
at the cell surface and presenting them to tyrosine kinase receptor (RTK) complexes (i.e., 
c-Met, EGFR), this receptor has been associated with the activation of a number of signaling 
pathways involved in cell proliferation, adhesion, invasion and metabolic shift [7,8]. CD44 
has also been detected on TEVs, and together with the TEVs content, is thought to be 
involved in 'pre-metastatic' niche formation by binding to hyaluronan (hyaluronic acid, 
HA) is preferred, distal organs [9,10].
This review discusses the involvement of CD44 in association with TEVs in cancer 
progression with the emphasis on 'pre-metastatic' niche formation and metastasis. It 
focuses on the modifications inflicted by this receptor upon delivery via TEVs to the target 
cells, due to its multifaceted role in intracellular signaling.
2. 'Facts Check'— CD44 Receptor
CD44 is a receptor described as a single span transmembrane glycoprotein without 
kinase activity whose ubiquitous and constitutive expression has been observed on many 
different cells. It can also exist as an integral component of the extracellular matrix (ECM) or 
as a soluble protein found in body fluids [11]. Each of these protein forms plays biological 
roles, which may be shared or distinct [11].
The membrane form of CD44 is a receptor that binds ECM ligands, such as hyaluronan 
(HA), collagen, osteopontin, laminin, fibronectin, and others. The structure of CD44 in its 
standard (CD44s) and variant (CD44v) form is presented in Figure 1. CD44 is encoded by 
a single gene, which in humans is composed of 20 exons [12]. The schematic CD44 gene 
structure is presented in Figure 2. CD44s is composed of the homologous N-terminal and 
C-terminal domains only. The N-terminal domain is encoded by exons 1-5, whereas the 
C-terminal domain is encoded by exons 16-20. The molecular mass of CD44s is usually 
between 80-85 kDa. Multiple variant forms (CD44v, v1-v10) are generated by alternative 
splicing of exons 6-15, and are composed of both the N- and C-terminal domains and 
an additional variant domain(s). W hile CD44s is found in a wide variety of tissues, the 
CD44v isoform seems to have a much-restricted distribution and is observed to be present 
in keratinocytes, activated lymphocytes, macrophages, and some epithelial cells [13]. In 
both CD44 forms, the N-terminal domain binds the physiological ligands. CD44v isoforms 
are enriched in binding motifs, which promote the interactions with microenvironment 
components and may serve as co-receptors for growth factors, such as EGF and HGF [14]. 
Structural diversity of CD44 is also generated by posttranslational modification, such as 
phosphorylation, glycosylation, and attachment of glycosaminoglycans [11,15]. Resting 
cells show a low-affinity for binding CD44 ligands; however, cellular activation can induce 
a transition of CD44 to a high-affinity state that mediates binding to HA. The transition from 
the "inactive" low-affinity state to the "active" high-affinity state of CD44 can be induced 
by soluble factors, including cytokines [16,17]. Activation of CD44 leads to clustering and 
initiation of intracellular signaling pathways, such as ERK1, 2, AKT, FAK, Rho, Src, etc. 
(reviewed in [7]). Tumor cells express CD44 in a high-affinity state with the capacity for 
constitutive binding of HA [18]. The soluble and/or integral with ECM forms of CD44 are 
generated by metalloproteinase-inflicted (mainly MT1- and MT3-MMPs) shedding from a 
cell's membrane [19]. The soluble CD44 protein can also be also produced by alternative 
splicing [20]. This form has been detected in the circulation and other body fluids, such 
as lymphatic, arthritic synovial, and bronchoalveolar fluids, as well as in cancer patients' 
serum [21- 23]. Soluble CD44 overexpression blocks cancer cell adhesion to HA [24] and is 
associated with aggressive growth and unfavorable prognosis for a patient.
Figure 1. CD44 structure in its standard (CD44s) and variant (CD44v) forms.
Figure 2. CD44gene structure. CD44s form is encoded by exons 1-5 and 16-20 only, whereas CD44v form undergoes 
alternative splicing (exons 6-15).
3. Hyaluronan— The M ajor Ligand of CD44
As mentioned above, CD44 binds to a  number of ligands; however, hyaluronan 
(hyaluronic acid, HA) ir its most specific ligand that is recognizable by bosh standard 
and variane forms of this raceptor [7i . HA is an anionic, non-sulfated polysaccharide that 
belongs to glycosaminoglycana. Its basic disaccharide monomer is a D-glucuronic acid 
linked with N-acetyl-D-glucosamine by glycosidic bonds (ß1-4 , ß l-3 ) . The schematic 
struclure of HA is (resented in Figure 3 . The molecular weight of OSA varies from HfS 
ter 107 Da and depends ora its tissue origin. In contrast to o)her gincosaminoglycans, 
HA ic synrhesized by three HA syathases (HAS 1-3) at th e ce ll surface (not in Golgi 
apparatus) [25] and is releas ed info the exCracellular spacc. HA is a major component of 
ECM, which supports tissue organization and contributes to crucial processes, such as cell 
migration, proliferation, survival, etc. [26].
The downstream effects of HA binding depend on its molecular weight. Under normal 
circumstances, HA, in its "native state", represents a high-molecular weight protein of 
about 1000 kDa [27] with anti-angiogenic, anti-inflammatory, and proliferation inhibiting 
activities [28]. On the other hand, HA in its 'fragmented state', with a molecular weight 
below 500 kDa, stimulates proliferation and migration of cells, induces an immune response, 
e.g., by increasing expression of inflammatory genes in human macrophages [27,29], the 
formation of immunosuppressive macrophages [30], death of activated T cells [31], and 
augments angiogenesis [28].
A number of studies have shown that HA is produced in abundance by malignant 
and stromal cells supporting the growth of tumors (breast [32], bladder [33], prostate [34]
colorectal cancer [35]), and correlates with tumor aggressiveness in humans [30,35]. HA 
facilitates tumor cell proliferation, cell-to-cell adhesion and protects them from the immune 
cell response [36]. The balance between HA contradictory activities is governed by a com­
plex system of HA synthases and hyaluronidases (Hyal), which regulate its degradation. 
Tumor cells have been reported to secrete excess amounts of hyaluronidases with the ability 
to cleave high molecular weight HA into smaller fragments (10-40 oligomers) [37], which, 
in turn, promoted CD44 cleavage [38]. Enhanced cleavage of CD44 was shown to facilitate 
tumor cell motility, which has been observed in many human tumors, including breast, 
colon, gastric, ovarian, lung, and others [37]. It has been shown that HA is involved in 
cancer cell, lymphocyte, and neutrophil motility in a CD44-dependent manner, however, 
the expression of this receptor alone was insufficient for chemotaxis towards HA [39,40]. 
Data on the binding efficiency of HA to CD44s and CD44v are conflicting. Bennett et al. 
reported that CD44s binds HA more efficiently than CD44v [41], however, other authors 
presented convincing data showing HA's affinity to both receptors to be similar [42].
OH
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Figure 3. Structure of hyaluronan (HA).
4. CD44-HA Interactions
There is quite an extensive number of surface receptors that recognize either the 
soluble or molecular form of HA. These include proteins, tuch as CD44, RHAMM, TSG- 
6/TN FIP6, Brevican, SHAP, LYVE4, TLRs, and others [26]. The RHAMM a id  TLR2,4 
receptors preferentially bind smaller- HA molecules (below 7 kDa), whereas CD44 requires 
at least six monosaccharides for the; process to occur [re-viewed in [43]. CD44 contains at 
leost three HA binding sites on the hair loop (encoded by exon 2 Lnd 5). CD44 molecules 
have been reported to tie present in three functional stages: Constitutive binding of HA 
(most of the tumor- cells), non-binding or non-binding until activated by physiological 
stimuli [7,44], The affinity ot HA )o CD44 is cell-type dependent, regulated by glycosylation 
in the receptor's extracellular domain and the phosphorylation of the seeine residue in the 
cytopiasmic tail [45]. fill forms of CD44 (standard or variants) can bind HA. In the case 
of immune cells, CD44 was described ae the only receptor thaf has been demonstcated to 
bind HA [40].
U p tn  HA binding So the intercellular domain, CD44 undergoe s confoemational 
changes resulting in the recruitment of adaptor proteins (ERM, Src, etc.) to its intra­
cellelar domain, which, in turn, leads to the activatien of a num bir ot signaling pathways 
involved in cell proliferation, adhesion migration, invasion and metobolic shift [8,46]. 
Table 1 summorizes all the currently known sitn al trantduction mechanism a and their 
outcomes associated with CD44 molecule; in cancer cells. Moreover, CD44v isoforms can 
also serve as co-receptors with the ability to sequester growth factors (i.e., HGF, FGF, 
EGF) a) the cell surface and p resenting them to tyrasine kinase receptor (RTK) complexes 
(i.e., c-Met, EGFR), which in turn, upon activation, can initiate an appropriate signaling 
pathway. Figure 4 depicts possible intercellulac signaling msdiated by the CD44 receptor in 
cancer cells.
CD44-HA interactions were defined as important for many types of cells. For example, 
macrophages exhibited preferential migration towards HA-enriched stromal structures in 
breast cancer [46]. It was also shown that small HA induced immunophenotypic maturation
of human monocyte-derived dendritic cells a n d a n  increase in their pro-inflammatory 
cytokine (IL-1, TNF, and IL-12) production [47]. An elevated expres sion of CD44 has 
been reported on activated T cells [27]. The CD44-dependent adhesion mechanism is 
likely to be the most important for mobilizing the effector T cells at sites of infection and 
inflammation, because the expression of CD44 is upregulated whereas L-selectin (CD62L), 
the lymphocyte-expressed selectin, is downregulated in these cases [48]. Activation of 
CD44 influenced tumor cell metabolism by inducing; Hypoxia-inducible factor 1a  (HIF1a) 
binding to nuclear DNA to increase glycolysis, in turn, rendering a metabolic shift in cancer 
cells [49].
Receptor activation
Angiogenesis Metabolic shift Cancer progression Cancer metastasis
in cancer cells
Figure 4. Signaling pathways engaging the CD44 receptor in cancer cells (according to [7] with 
own modifications).
Table 1. Association of the CD44 molecule with signaling pathways in cancer cells.
Signaling Pathway Outcome Reference
ERM/MAPK Cell division, proliferation [50]
CD44s PI3K/AKT/NFk B Inflammatory cytokine release [51]







Met/PI3K/AKT Cell invasion [55]
Met/Snail/MMP Cell division, proliferation [56]
5. EM T and the Role of CD44 and TEVs
Prior to tumor cell dissemination, cancer cells in the primary tumor have to undergo 
epithelial-mesenchymal transition (EMT), which in the case of cancer is categorized as 
type III. EM T is a transdifferentiation process, crucial for tumor growth and progression, 
that allows cancer cells to detach from the basement of the tumor by undergoing changes 
necessary to reach mesenchymal phenotype and morphology. This step is characterized 
by HA overproduction [57], switching cadherin type from E to N, morphological changes 
(long shape, filopodia forming), and EVs secretion [6,58,59]. During the next phase of EMT, 
tumor cells undergo genetic and epigenetic changes favoring their dissemination, which 
are induced by specific signals that are still mostly undefined. However, factors, such as 
HGF, EGF, PDGF, and TGFß, released by cells surrounding the tumor are considered to be 
very important in this process. There is also evidence, that transcription factors, such as 
Snail, Slug, and ZEB1, are crucial for the regulation of EMT [60].
Cho et al. reported the role of CD44 molecule in induction of EMT in SW480 colon 
cancer cell line [58]. In this case, activation of CD44 (e.g., ligand binding) initiated cy- 
toskeleton changes (via ezrin-radixin-moesin connection) and MT1-MMP activation, which, 
in turn, promoted EG FR /A kt signaling pathway and downregulation of E-cadherin [58] . 
Others have also reported that CD44 interaction with HA induced malignant behavior of 
the tumor cells, which resulted in the initiation of several pathways, such as src/M A PK, 
PI3/A kt, and translocation of S n a il/ß-catenin to the nucleus [61]. In this auto-regulating 
loop, HA content on the surface of the tumor cells and between them is regulated by CD44 
molecules, which induce HAS expression [6].
One of the modes aiding EMT involves EVs. EVs, in general, comprise a heteroge­
neous, membrane-bound population of vesicles that are released by different types of cells, 
including tumor surrounding cells (i.e., CAFs, macrophages, etc.) and cancer cells. EVs 
are found to be present in many biological fluids, including plasma, saliva, urine, seminal 
fluid, etc. [1], and are thought to play an important role in intercellular communication. 
Recently, TEVs were reported as a substantial contributor in EMT in cancer cells [62]. It 
was shown that treatment of noninvasive urothelial cells with TEVs isolated from invasive 
bladder cancer cell-conditioned media caused overexpression of, besides other factors, 
Snai1 in these cells, which resulted in their increased migration and invasion abilities [63]. 
In another study, human bronchial epithelial cells (HBECs) were exposed to either TEVs iso­
lated from late-stage lung cancer patients or highly metastatic lung cancer cell-conditioned 
media [64]. In both cases, the exposed HBECs exhibited vimentin overexpression and 
EMT induction (upregulation of N-cadherin and the reduction of E-cadherin and ZO-1 
expression), which later resulted in their elevated migratory, invasive, and proliferative 
capabilities [64]. Not surprisingly, EVs released by stromal cells can also induce EMT in 
cancer cells. EVs obtained from CD81+ CAFs subpopulation caused the autocrine release 
of Wnt11 from breast cancer cells (human breast MDA-MB-231 adenocarcinoma), resulting 
in their increased motility [65]. In a different study, enriched cargo of miRNA-21, -378e, 
and -143 was detected in CAF-derived EVs [66]. Treatment of breast cancer cells (BT549, 
MDA-MB-231, and T47D cell lines) with these EVs resulted in an increase in their capacity 
to form spheroids as portrayed by the expression of stem-cell and EMT markers [66]. En­
hanced invasion and EMT promotion were also observed in tumor cells of the SKOV-3 and 
CAOV-3 cell lines that were exposed to CAF-derived EVs [67]. In this case, the isolated 
CAF-derived EVs carried elevated levels of TGFß1, which promoted activation of the 
SMAD signaling pathway in these tumor cells [67].
CD44 has been reported to be present on TEVs derived from gastric cancer cell 
lines [6,68], ovarian [69], pancreatic [70,71], and primary mesenchymal cells [72]. The 
presence of HA-coated and CD44+ TEVs has been detected after their release by gastric 
cancer cells [6]. However, due to the limited knowledge regarding the molecular weight of 
HA carried by TEVs, it is difficult to predict their impact on EMT. For the most part, it is 
assumed that TEVs HA content potentially reflects the one from the cell of origin [72,73]; 
however, this issue needs further confirmation. TEVs carrying HA, oncogenes, miRNAs,
and other ECM components can exert their impact by fusing with the cell membrane or 
by being engulfed by the target cells. In both cases, TEVs can influence target cells by 
delivering their content either directly (horizontal transfer) or indirectly through signaling 
pathway activation. It has been shown that TEVs carrying MMPs may remodel ECM 
[described in detail in [74- 76] by downregulating E-cadherin expression, degrading ECM 
components, and upregulating MMP-9, which, all together, facilitated tumor dissemina­
tion [69]. Others observed that TEVs-delivered HA induced motility of CD44+ CAFs and 
cancer cells [reviewed in [77], and that CD44+ tumor cells present in the blood [77- 79] 
exhibited characteristics of cancer stem cells. Expression of this receptor on these cells 
might results in their dissemination into niches (organotropism) that might be possibly 
prepared by HA-coated TEVs (see below).
6. Cancer M etastasis and TEVs
Cancer metastasis is the final stage of tumor progression. It is defined by the arrival of 
primary tumor cells at other sites of the body, followed by their proliferation and formation 
of new tumors. The whole process of cancer metastasis can be divided into four main 
stages: Intravasation (from primary tumor sites to blood vessels), extravasation (from 
blood circulation to future metastasis sites), tumor latency, and formation of micrometas­
tasis and macrometastasis [80]. Although it has been over a century since Steven Paget 
published his "seed and soil" hypothesis, stating that metastasizing cancer cells exhibit 
organotropism, the mechanisms underlying this phenomenon are still a mystery. Each 
stage of cancer metastasis seems to be governed by a number of different events (e.g., 
epithelial-mesenchymal transition, reverse mesenchymal-epithelial transition, extracellular 
matrix remodeling, etc.), however, the actual triggers an d /o r mediators of these events 
are still elusive. There is growing evidence that these 'm issing links' between the stages 
comprising cancer metastasis might be filled by TEVs [81]. The overall cancer metastasis 
mechanism emphasizing TEVs involvement is graphically presented in Figure 5 . Table 2 
summarizes the content of the cargo carried by CD44s/CD44v-positive TEVs and depicts 
the impact these TEVs exert on different cellular processes.
Figure 5. Schematic representation of the involvement of CD44/HA and TEVs in cancer transition from the primary tumor 
to metastasis.
Table 2. Association of CD44s/CD44v-positive tumor-derived extracellular vesicles (TEVOs and their cargo content with 
the impact on cancer progression.
Type of Cancer CD44 form Carried by TEVs Cargo of TEVs Role Reference
Head and neck CD44s, CD44v3 PD-L1, FasL, TGF-ß, EGFR Immunosupressive biomarker of disease [82]
Bladder CD44s MUC-1, EMMPRIN, HLA I, integrins disease monitoring, [83]
CD44s HA, EGFR, ADAM10 Cancer progression [42,84,85]
MMP2,-7,-9,-13,-14,-17,
Colon CD44v6
ADAM10, ADAM17, CD26, 
uPAR TIMP1, TIMP 2 
CXCR4, MET, EpCAM, 
Tspan8, integrins
Motility and invasion 
promotion [71]
CD44s, CD44v6
MET, EpCAM, integrin, 
CXCR4, uPAR, ADAM17, Motility and invasion [71]
Pancreas MMP2, 9, 7,13,14
promotion
CD44s, CD44v7-8 EpCAM, EMMPRIN, mRNA for VEGF, IL-8, HGF interaction with monocytes [70]
Ovarian CD44s n.a. Invasion promotion [69]
Breast CD44s n.a. Drug resistance [86]
Gastric CD44s HA ECM interactions [6]
Prostate CD44s, CD44v8-10 CD44v8-10 mRNA Drug resistance [87]
6.1. Tumor Cell Intravasation
The concept of tumor cell intravasation involves the ability of cancer cells to invade 
into the normal tissue, often towards lymphatic or blood vessel, and then cross the endothe­
lial barrier to enter circulation [87]. This process involves many different factors, including 
the presence of other cells in the tumor microenvironment, signaling molecules, proteases, 
and the proper environmental conditions at the tumor site and vasculature. Altogether, 
these factors play specific roles in allowing the cancer cell to invade through the basement 
membrane, adhere and pass through the endothelial cell junctions for circulation entry [88].
In the study involving large oncosomes (also referred as TEVs) isolated from the 
LNCaP prostate adenocarcinoma cell line, it was shown that they contained bioactive 
matrix MMP-2 and -9, key proteases involved in tumor cell invasion [89]. This finding 
allowed the authors to speculate that large oncosomes may cause degradation of the ECM 
and the release of endothelial permeabilization factors that facilitate intravasation [89]. 
MMP-14 has been demonstrated to be actively loaded into TEVs by the v-SNARE and 
VAMP3 proteins in amoeboid-like invasive tumor cell lines [71]. TEVs release by these 
tumor cells caused an increase in ECM degradation [71]. It was also reported that TEVs 
released by human renal cancer stem cells contained, besides other factors, MMP-2 and -9 
mRNA, and that they were responsible for the preparation of favorable conditions for lung 
metastasis [90]. In another study, TEVs derived from a number of hypoxic lung cancer cell 
lines (CL1-5, NCI-H1437, -H1648, -H1792, and -H2087) carried miR-23a, which caused the 
suppression of prolyl hydroxylase 1 and 2 (PHD1 and 2) in endothelial cells leading to the 
accumulation of HIF-1a, known for its role in angiogenesis. Moreover, TEVs miR-23a also 
inhibited tight junction protein ZO-1, resulting in an increase in vascular permeability and 
cancer cell intravasation [91].
There is also growing evidence that CD44s/CD44v-TEVs may play a pivotal role in 
cancer cell intravasation. The importance of CD44v6 in the process of metastasis was first 
presented in the studies involving rats and highly metastatic BSp73ASML (ASML) cell
line with a selective knockdown of the CD44v6 gene (CD44v6kd) [92,93]. Based on the 
obtained data, it was concluded that the CD44v6kd tumor cells were unable to grow and 
that the rats remained tumor-free. However, the matrix obtained from wt ASM L cell line 
sufficed for metastasis development. The separation of TEVs from this matrix revealed 
that they are mainly bound to HA, laminin, and collagen. These TEVs also contained high 
amounts of proteases and were able to degrade ECM proteins, a prerequisite of cancer cell 
intravasation [10,92].
Recruitment/transformation of a specific type of cells in the site of the primary tumor 
microenvironment enables successful cancer cell intravasation. A key feature in this process 
is the differentiation of stromal fibroblasts into myofibroblasts, which is associated with 
TGFß and SM AD-dependent signaling [94,95]. There are numerous reports implying 
that tumor cells deliver TGFß to fibroblasts by TEVs release, which initiates fibroblast 
differentiation [94,96]. It was also shown that transfer of MMP-inducer EMMPRIN by 
TEVs derived from lung cancer cells to fibroblasts led to MMP expression in the latter and 
ECM remodeling at the tumor site, thus, aiding tumor cell invasion [97].
Macrophages represent another type of cells that seems to play a major role in tumor 
cell intravasation [88]. Tumor cells can recruit and reprogram macrophages to support their 
growth and spread, which may well be facilitated by TEVs. One such example involves 
EGF/CSF1 paracrine loop between breast cancer cells and macrophages, where tumor cells 
secrete CSF1 to recruit macrophages, and in turn, macrophages release EGF to stimulate 
tumor cell invasion towards blood vessels [98]. Once at the endothelial barrier, proteases are 
being produced by both macrophages and tumor cells, enabling tumor entry into the blood 
vessel [99]. It has been shown that this direct interaction between the two types of cells 
is contact-dependent and results in the formation of tumor cell invadopodia allowing the 
tumor cell penetration through the tight endothelial junctions and bloodstream entry [100].
Cancer initiating cells (CIC) are believed to be a population of cells that are specifically 
engaged in metastasis. Invadopodia of these cells are crucial structures responsible for ECM 
degradation, and subsequent tumor cell migration and invasion [101- 105]. CD44s/CD44v, 
being one of the CIC markers, is often associated with invadopodia. In colorectal carcinoma 
(CRC), binding of HA by CD44v6 causes the secretion of MMP-2 and -9, leading to changes 
in the ECM [106,107]. The presence of MMP-2 in this scenario may potentially result in 
the degradation of type IV collagen, a component of the basement membrane, causing 
tumor invasion [108]. Furthermore, the association of OPN with the ectodomain of the 
CD44v6 molecule leads to the phosphorylation of its intracellular domain, which, in turn, 
causes CCL5, CXCL12, and M M P-/-9 gene upregulation leading to the increase of CRC 
invasiveness [109]. There also seems to be an interplay between the CD44v6 receptor and 
the CCL12/CXCR4 signaling axis [110]. Treatment of non-metastatic CRC cells with CCL12 
led to the acquisition of the CD44v6+ phenotype and the ability of these cells to form 
metastasis [111]. On the other hand, blocking of the CCL12/CXCR4 interaction caused 
reduced expression of CD44v6 in CRC stem cells [111]. In the presence of CCL12, there is 
an interaction between the intracellular domains of CD44v6 and CXCR4 receptors, whereas 
knockdown of CD44 impairs the CCL12-mediated CXCR4 signaling [112]. Altogether, it is 
reasonable to assume that the presence of CD44s/CD44v in the invadopodia of CIC is not 
a coincidence and that, together with other receptors, facilitates tumor cell metastasis with 
the emphasis on the initial phase of this process, namely, intravasation.
6.2. Tumor Cell Extravasation
The process of cellular passage from the bloodstream into the tissue is referred to as 
extravasation. The stages of this process seem to be conserved regardless of the type of 
cells involved, however, the most prominent cells engaged in this phenomenon are leuko­
cytes, i.e., T lymphocytes, natural killer (NK), neutrophil granulocytes, and monocytes. 
Extravasation can be divided into three steps. The first step is characterized by the cells' 
loose interaction through its surface receptors with vascular endothelium followed by 
their rolling along the blood vessel surface. The second step is characterized by a firm
attachment of the cells to the endothelium, where a different set of receptors is being 
utilized. During the next, third step, referred to as diapedesis, the cells spread out on the 
endothelium and actively pass through the endothelial barrier [113]. The role of EVs in 
extravasation is still elusive, although, reports are emerging suggesting their involvement 
in this process. It has been reported that miR-181c delivered by TEVs obtained from brain 
metastatic cancer cells downregulated 3-phosphoinositide-dependent protein kinase-1 
(PDPK1), causing cofilin-induced modulation of actin dynamics in the blood-brain barrier, 
which resulted in an increase in its permeability [114]. Furthermore, repeated exposure 
to these TEVs promoted preferential metastasis of breast cancer cells into the brain [114]. 
Zhou et al. showed that miR-105, a potent regulator of ZO-1, present in TEVs obtained from 
metastatic breast cancer cells, was able to completely destroy tight junctions in epithelial 
monolayers [115]. There are in vivo studies where anti-miR-105 treatment was employed 
resulted in suppressed brain metastasis [115]. Chemokines and their receptors, considered 
as important factors in tumor cell extravasation, were reported to be transported by TEVs. 
For example, elevated levels of SD F-1/CXCL12 and CXCR4 bearing TEVs were found 
to be present in the peripheral blood and bone marrow plasma samples of patients with 
acute myelogenous leukemia (AML) [116]. Moreover, these TEVs were able to transfer the 
CXCR4 receptor to AML-derived HL-60 cells, enhancing their migration to SDF-1 in vitro 
and increasing their homing to the bone marrow of irradiated N O D /SCID /beta2m  (null) 
mice [116]. Chen T et al. also detected the presence of CCL2, CCL3, CCL4, CCL5, and 
CCL20 in TEVs generated by tumor cells undergoing heat stress [117]. Others reported that 
the release of CCL2 by colon carcinoma cells and its subsequent interaction with the CCR2 
receptor present on endothelial cells resulted in vascular permeability [118]. Consequently, 
an increase in tumor cell extravasation was observed [118].
There are no direct reports pointing to the involvement of CD44/CD44v+ TEVs in ex­
travasation of the tumor cells. However, CD44v6 expression in cells, such as macrophages, 
has been attributed to their ability to extravasate into tissue [119]. Since tumor cell in- 
travasation and extravasation depend on the disruption of tight endothelial junctions, it is 
reasonable to speculate that once in circulation and under certain conditions, TEVs with 
appropriate content (i.e., CD44, HA, miR-181c, -105, CCL2, etc.) can disrupt vascular tight 
endothelial junctions enabling the docking and passage of disseminating cancer cells.
6.3. Tumor Latency
The original concept of tumor latency, defined as a time interval between the exposure 
to a cancer-causing factor until cancer diagnosis, has changed dramatically over time [120]. 
With the current knowledge on this topic, it has been proposed that tumor latency is 
a complex, multifactorial process that cannot be traced to one, single event. On the 
contrary, it is widely accepted that this process takes time and that exposure to a cancer- 
causing agent only accelerates it [120]. One of the factors that may have an impact on 
the acceleration of tumor latency is CD44. It has been shown that CD44+, and not CD44-, 
tumor cells sorted out from the primary mouse xenografts of non-small cell lung cancer 
(H1299) tumors exhibited shorter tumor latency in the subsequent tumor formations [121]. 
Analogically, in nasopharyngeal carcinoma, tumor cell xenografts of the HK1 cell line with 
high expressions of CD44 and EpCAM showed a more rapid growth than the ones where 
tumor cells' expression of CD44 was diminished [122]. As with tumor cell extravasation, 
there is no evident data suggesting direct involvement of CD44+ EVs in tumor latency. 
Studies that undertake this phenomenon are required to fully understand their possible 
impact on this process.
6.4. Pre-Metastatic Niche Formation
The most studied aspect of metastasis where TEVs seem to play an important role involves 
pre-metastatic niche formation that occurs prior to macroscopic tumor cell invasion [123]. Pre­
metastatic niche refers to the microenvironment, which is well prepared for tumor cells to 
colonize and disseminate to distant organ sites [124]. This process is multilateral, however, it
has been proposed that several key components released by different types of cells are required 
for its occurrence. These components include secreted factors from tumor cells (VEGF, PIGF, 
S100A 8/A9, etc.), bone marrow-derived cells (VLA-4, Id3), suppressive immune cells (HSF1, 
girdin, fibronectin, etc.), host stromal cells (TGF-ß, TNF-a, G-CSF, etc.) and/or delivered by 
extracellular vesicles (MIF, OPN, microRNA-122, etc.) [125].
Among many different types of EVs taking part in metastasis, CD44s/CD44v-positive 
TEVs released by CICs are gaining considerable attention in the process of pre-metastatic 
niche formation. In the study by Jung T et al. [9], it was shown that the overexpression of 
CD44v6 promoted metastasis, which was confirmed by a selective knockdown of CD44v4- 
v7 (ASMLkd) in the highly metastatic BSp73ASML cell line (ASMLwt). The authors argued 
that the settlement of metastasizing tumor cells required the establishment of special 
niches in pre-metastatic organs, which was facilitated by the combination of soluble matrix 
and TEVs derived from these cells. They observed that CD44v6 played a central role 
in assembling the proper soluble matrix, which supported TEVs in the modulation of 
target cells in the pre-metastatic organ. The involvement of CD44 was also observed 
in the promotion of ovarian cancer invasion into the peritoneal cavity. In this case, the 
CD44+ TEVs released by the tumor cells of the HeyA8 ovarian cell line were able to 
transfer this receptor onto the human peritoneal mesothelial (HPMCs) cells. This, in 
turn, caused the reprogramming of the HPMCs cells to a more EMT phenotype, which 
led to an increase in ovarian cancer cell invasion and metastasis [69]. In another report 
concerning the degree of glioblastoma invasiveness, TEVs released by several glioblastoma 
cell lines were analyzed using mass spectrometry, and their specific marker profile was 
assessed [126]. The gathered data suggested a strong association between the TEVs CD44 
expression and the level of invasiveness of the tested cell lines. The authors speculated 
that higher TEVs CD44 expression correlated with the more aggressive glioblastoma cell 
line, indicating their potential involvement in metastasis in this type of cancer. Another 
example of pre-metastatic niche formation where TEVs CD44 seems to play a crucial role 
involves pancreatic cancer progression [127]. The authors of this study demonstrated 
that CD44 not only interacted with integrin a6ß4 and promoted tumor cell proliferation, 
migration, and invasion by regulating signaling pathways (Ras and ERK), but was also 
transferred by pancreatic TEVs to the liver cells- a common site of metastasis for this type 
of tumor. The authors argued that by interacting with the a6ß4 integrin in the liver, CD44 
generated a pre-metastatic milieu to facilitate specific organ metastasis by upregulating 
molecules, such as CD133, a-sm ooth muscle actin (a-SM A), and interleukin-6 (IL-6) in 
target liver cells [127].
7. Conclusions
The inability of the immune system to fully recognize tumor cells as foreign entities 
very often results in fatalities. The array of factors (cytokines, growth factors, receptor 
shedding, etc.) that tumor cells release into the surroundings to prevent or limit the immune 
response shows the type of arsenal at tumors' disposal. In addition to these factors, tumor 
cells release TEVs, which not only modify the proximal tumor microenvironment, but 
also distal niches for future tumor cell dissemination. The release of TEVs with active 
receptors, such as CD44, with capabilities of physical interactions and intracellular signaling 
interference in other cells, has proven for tumors to be very effective in maintaining further 
progression/development. Organotropism of TEVs, such as CD44+TEVs, exemplifies the 
potential steps underlying the mechanisms involved in cancer metastasis; a critical step in 
determining the outcome of tumor treatment. Based on the accumulated information in this 
review, anti-tumor therapies aiming at the simultaneous blocking of both TEVs-directed 
CD44 loading and TEVs release might substantially undermine tumor spreading. This 
type of targeted interference, encompassing several critical points of cancer metastasis, 
presents a credible possibility of anti-tumor therapy that will bring humankind closer to 
the ultimate goal of defeating this disease.
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TEVs tumor-derived extracellular vesicles
EVs extracellular vesicles
CD44 cluster of differentiation 44
CD44s cluster of differentiation 44 standard isoform





RTK receptor tyrosine kinase
MMP matrix matalloproteinase
CIC cancer initiating cell
EMMPRIN extracellular matrix metalloproteinase inducer
EGFR epidermal growth factor receptor
CAFs cancer associated fibroblasts
CRC colorectal carcinoma
HIF1a Hypoxia-inducible factor 1-alpha
ERM ezrin-radixin-moesin
MAPK mitogen-activated protein kinase
PI3K phosphoinositide 3-kinase
AKT alpha serine/threonine-protein kinase
NFkB nuclear factor kappa-light-chain-enhancer of activated B cells
ICD intracytoplasmic domain
RHAMM receptor for hyaluronan-mediated motility
cSrc proto-oncogene tyrosine-protein kinase Src
RAS proto-oncogene protein p21
FAK focal adhesion kinase
Met hepatocyte growth factor receptor
Snail zinc finger protein SNAI1
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